Talazoparib - Pfizer

Drug Profile

Talazoparib - Pfizer

Alternative Names: BMN-673; BMN-673ts; LT 006673; LT-00673; LT-673; MDV-3800; Talazoparib tosylate

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEAD Therapeutics
  • Developer BioGene Pharmaceutical; BioMarin Pharmaceutical; Center Trials & Treatment; National Cancer Institute (USA); Pfizer; St. Jude Childrens Research Hospital; University of California at San Francisco; University of Maryland Greenbaum Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Fluorobenzenes; Phthalazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Breast cancer
  • Phase III Prostate cancer
  • Phase II Cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia
  • Phase I Ewing's sarcoma
  • Preclinical Glioblastoma; Non-small cell lung cancer
  • No development reported Pancreatic cancer
  • Discontinued Haematological malignancies

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-0 development in Ovarian-cancer(First-line therapy, Neoadjuvant therapy) in USA (PO, Tablet)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Pancreatic-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (PO)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Pancreatic-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top